Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Daewoong Pharmaceutical : invites medical specialists from China for the successful ‘Global Ursa Forum'

share with twitter share with LinkedIn share with facebook
share via e-mail
07/23/2014 | 09:28pm EDT

- To exchange with medical specialists abroad for various activities for global business

- Invited about 60 specialists in the digestive tract from China to discuss Ursa's clinical value and exceptional efficacies

Daewoong Pharmaceutical Co., Ltd. (President Jong Wook Lee) held the 5th Global Ursa Forum for two days on the 10th and the 11th at Sejong Hotel in Myeong-dong, Seoul with about 60 medical specialists from China.

Celebrating its 5th anniversary this year, the Global Ursa Forum is an annual event held to introduce to the world Ursa's clinical value and the medical excellence of Korea.  The event invited Professor Sang Hyup Lee of Seoul National University Hospital and Professor Sang Hoon Ahn of Yonsei Severance Hospital along with about 60 medical specialists from China to discuss the various efficacies of Ursa.

The medical specialists of Korea and China spoke for the forum to share the clinical studies of Ursa for the liver, gall bladder, and pancreas diseases of each country.

Professor Sang Hyup Lee of Seoul National University Hospital's Department of Digestive Medicine presented about 'Ursa's outstanding effect for dissolving and preventing the gallstone', while Professor Sun Wenbing of Capital Medical University's Department of Liver and Gall Bladder talked about 'Ursa's expected effect on the surgical treatment of cholelithiasis and prevention of gallstone after surgery'.  Also, Professor Sang Hoon Ahn of Yonsei Severance Hospital's Department of Digestive Medicine spoke about 'The latest cases of treatment of chronic viral hepatitis and Ursa's efficacies', while Professor Feng Yanhong of Nanjing 2nd People's Hospital's Department of Digestive Medicine spoke about 'The diagnosis and treatment of cholestatic liver disease and Ursa's efficacies'.

"Many overseas specialists specialized in the digestive tract are applying for training in Korea through the annual Global Ursa Forum," said Professor Sang Hyup Lee.  "It is a great opportunity to academically exchange with many global specialists and introduce Korea's medical excellence to the world."

"The viral hepatitis requires both antiviral treatment and the repair of hepatic functions to prevent the aging and degeneration of liver," said Professor Sang Hoon Ahn.  "I hope that the multinational clinical study of hepatic treatment for the vital hepatitis with the medical specialists specialized in the digestive tract can expand the indication of efficacies."

"Ursa is being exported to about 10 countries, including China, Vietnam, and the Philippines, and we are planning to expand the market to Australia, Europe, and USA," said President Jong Wook Lee of Daewoong Pharmaceutical.  "Ursa was launched in China in 2009 and has successfully been approved by all major cities in China to contribute to the academic exchanges between Korea and China and the explosive increase in sales through global clinical studies and marketing."

Ursa of Daewoong Pharmaceutical is constantly working with various pharmaceutical/ingredient fairs around the world, healthcare and medical delegations, and international/local symposiums for globalization.  In April 2012, it became the only pharmaceutical company to be selected for 'World-class 300', the government project to nurture 300 global companies by 2020, and received KOTRA's full support through the World Champ Project for global marketing to expand the global market for 300 billion KRW in sales by 2020.

News List

Prev The National Agency of Drug and Food Control of Indonesia visits Daewoong Pharmaceutical's Hyangnam Factory
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Companies"
05:28pSUNCOR ENERGY : No injuries as fire aboard Suncor's Terra Nova vessel extinguished
05:20pGLOBAL EAGLE ENTERTAINMENT : Official notification to shareholders of matters to be brought to a vote ("Proxy")
04:20pTHIN FILM ELECTRONICS ASA : - Registration of Share Capital Increase
04:16pHAMILTON BEACH BRANDS : ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Reminds Hamilton Beach Brands Holding Company Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – HBB
04:08pBOEING : Dragon-riding astronauts join exclusive inner circle at NASA
03:39pTESLA : SpaceX's Rocket Launches Successfully, Approaches Orbit
03:33pTESLA : SpaceX rocket ship blasts off into orbit with 2 Americans
03:16pMESA FINAL DEADLINE MONDAY : ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Reminds Mesa Air Group, Inc. Investors of Important June 1 Deadline in First Federal Securities Class Action Filed by the Firm – MESA
03:07pTESLA : Elon Musk's SpaceX Tries Again to Launch NASA Astronauts Into Orbit -- 6th Update
03:02pElixxer Ltd. Provides Update on Continuous Disclosure Filings Following Temporary Relief by the Canadian Securities Administrators
Latest news "Companies"